Boehringer Ingelheim Biopharmaceuticals China receives “Facility of the Year” Award
Shanghai, China,
- Boehringer Ingelheim’s commercial manufacturing site OASIS in Shanghai has been honored with an award in the ‘Facility of the Year’ program
- The International Society for Pharmaceutical Engineering has awarded the company the prize with an 'Honorable Mention'
- The facility impresses with its flexible and well thought-out concept
manufacturing facility in Shanghai
has been awarded as “Facility of the
Year”
Shanghai, China, April 9 2020 – Boehringer Ingelheim Biopharmaceuticals China Ltd. has been awarded with a 2020 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE). The company received an Honorable Mention award for its commercial facility in Shanghai, which is located at Zhangjiang Hi-Tech Park, a leading R&D region characterized by strong innovative capacity.
Boehringer Ingelheim’s modern commercial facility OASIS is designed to fulfill a maximum degree of flexibility. It comprises a single use concept and accommodates flexible modular expansion to meet patient, business and market needs, taking into account state-of-the-art environmentally friendly energy systems. In addition, the modular concept supported a very short project timeline from fit-out to start of operation.
With the presentation of the award, ISPE clearly recognizes successful projects that have overcome significant challenges in planning, implementation and delivery. A special focus is on projects in new technologies or in demanding regions of the world, which is applicable for Boehringer Ingelheim’s biopharmaceuticals manufacturing facility in Shanghai.
With the presentation of the award, ISPE clearly recognizes successful projects that have overcome significant challenges in planning, implementation and delivery. A special focus is on projects in new technologies or in demanding regions of the world, which is applicable for Boehringer Ingelheim’s biopharmaceuticals manufacturing facility in Shanghai.
As the first and only biopharmaceuticals facility in line with global standards set by a multinational pharma company in China, Boehringer Ingelheim’s facility has become a major milestone in the company’s strategic blueprint for its biopharmaceuticals business globally.
This enabled Boehringer Ingelheim BioChina to actively participate in a trial project with the local authorities to establish a Marketing Authorization Holder (MAH)/ Contract Manufacturing Organization (CMO) model in China. The commercial facility was of essential significance for this regulatory refinement as it had provided evidence of a real product derived from this facility. A novel oncological monoclonal antibody was approved under the new regulatory setup in December 2019 and has since then been supplied to the Chinese market.
This enabled Boehringer Ingelheim BioChina to actively participate in a trial project with the local authorities to establish a Marketing Authorization Holder (MAH)/ Contract Manufacturing Organization (CMO) model in China. The commercial facility was of essential significance for this regulatory refinement as it had provided evidence of a real product derived from this facility. A novel oncological monoclonal antibody was approved under the new regulatory setup in December 2019 and has since then been supplied to the Chinese market.
By applying global quality standards and the same technology throughout the entire global manufacturing network, Boehringer Ingelheim is able to allow smooth transfers between its global sites. The set-up constitutes supply security at highest quality standards for customers and in the end, patients.
About the ISPE Facility of the Year Awards Program
Established in 2004, The Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. Visit ISPE.org/FOYA for more information.
About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.
The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.
For more information, contact:
Amy Henry
Marketing Communications Manager
International Society for Pharmaceutical Engineering (ISPE)
Tel: +1-813-960-2105
Amy Henry
Marketing Communications Manager
International Society for Pharmaceutical Engineering (ISPE)
Tel: +1-813-960-2105
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of
19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Boehringer Ingelheim is one of the world’s largest manufacturers of biopharmaceuticals. With over 35 years of experience in this field, the company is an industry pioneer and has produced more than 35 biopharmaceuticals for global markets. Represented by the brand Boehringer Ingelheim BioXcellence™, it offers tailor-made contract development and manufacturing services to the industry, providing the entire production technology chain from DNA to fill and finish through its network in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ secures supply throughout the entire product lifecycle — transferring customer projects at any stage, delivering to almost any scale and thereby making outsourcing easy.
For more information please visit www.bioxcellence.com
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Media Contacts
Head of Group Communications
Related Press Releases
December 30, 2019